ATHA
Athira Pharma, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Athira Pharma (ATHA) Stock: Buy, Sell, or Hold?
$6.75
-0.44 (-6.12%)
âŧ
5d:
-3.02%
30d:
+73.75%
90d:
+72.19%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (54%)
Quality Score
38/100
Position
FAIR
Forward P/E & Valuation
-1.3x
Next 12M consensus est.
Wall Street Target
$4.00
-40.7% vs target
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$6.41 / $7.77
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: ATHA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When ATHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: ATHA is currently trading at $6.75, which is considered fair based on recent price action.
Technical Outlook: Technically, ATHA is in a strong uptrend. Immediate support is located at $6.41, while resistance sits at $7.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATHA is in a strong uptrend. Immediate support is located at $6.41, while resistance sits at $7.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
38/100
(SELL)
Volume Confirmation
UNKNOWN
Confidence Score
53.7%
Trading Range & Key Levels
Support Level
$6.41
Resistance Level
$7.77
Current Trend
Strong Uptrend
Technical data as of
Jan 9, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BEARISH: Downward momentum (-6.1%)
- BEARISH: Trading 40.7% above Wall St target ($4.00)
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.34
Wall Street Target
$4.00
(-40.7%)
Share ATHA Analysis
Share this live ATHA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ATHA)
Bearish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Apr 14, 2026
Daily AI digest
AI Retail Discussion Summary:
Bearish sentiment prevails on $ATHA with one user expressing caution on StockTwits.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 16, 2026 1:59 PM ET
Data refreshes hourly during market hours. Next update: 2:59 PM
Data refreshes hourly during market hours. Next update: 2:59 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$300 | 60 HOLD |
|
ONC
BeOne Medicines AG |
STRONG BUY
27 analysts |
$469 | 36 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
STRONG BUY
32 analysts |
$595 | 35 SELL |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 63 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$315 | 34 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ATHA Research Pages
ATHA Technical Chart
ATHA Price Prediction
ATHA Intrinsic Value DCF
ATHA Earnings Date
ATHA Investment Advisor
ATHA Fair Price Analyzer
ATHA Target Price Playground
ATHA LEAP Simulator
ATHA Supply Chain Tear-Down
Engineering R&D & Supply-Chain Velocity Hub
AI Chip Cost & Reticle Wall Visualizer
House Thesis Scoreboard & Risk Guard
ATHA Competitors
Part B: Tradestie Flagship Market Scanners